Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy

Expert Opinion on Biological Therapy

Volumn 12, Issue 11, 2012, Pages 1427-1447

  Hiss, Donavon C ^a   Fielding, Burtram C ^a  

^a UNIVERSITY OF THE WESTERN CAPE   (South Africa)

Author keywords

Angiogenesis; Antitumor immune response; Apoptosis; Cancer gene therapy; Cancer hallmarks; Gene silencing; Gene directed enzyme prodrug therapy; Genetically engineered viruses; Genomic instability; Mathematical modeling; miRNA; Oncolytic virotherapy; Preclinical optimization; Proof of concept; Transcriptionally targeted suicide gene therapy; Tumor microenvironment

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; E1A PROTEIN; G 207; HYALURONIDASE; INGN 007; INTERLEUKIN 24; LONTUCIREV; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CELL AGING; CELL CYCLE ARREST; COMPUTER MODEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE SILENCING; GENE TARGETING; GENETIC ENGINEERING; GENOMIC INSTABILITY; GENOTOXICITY; GLIOBLASTOMA; HUMAN; HYPOXEMIA; IMMUNE EVASION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MATHEMATICAL MODEL; MELANOMA; MULTIMODALITY CANCER THERAPY; NEUROSURGERY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOLYTIC VIROTHERAPY; PANCREAS ADENOCARCINOMA; PROCESS OPTIMIZATION; PROSTATE CANCER; REVIEW; STEM CELL NICHE; TARGET CELL DESTRUCTION; TREATMENT OUTCOME; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CELL INTERACTION; VIRUS REPLICATION; ANIMAL; GENE THERAPY; GENETICS; NEOPLASMS; PROCEDURES; STANDARDS; VIRUS;

ANIMALS; GENETIC ENGINEERING; GENETIC THERAPY; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRUSES;

EID: 84867300567     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.707183     Document Type: Review

References (172)

1. Sinkovics J, Horvath J. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp 2008;56(0):1-59
2. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007;254(2):178-216
3. Komarova NL, Wodarz D. ODE models for oncolytic virus dynamics. J Theor Biol 2010;263(4):530-43
4. Wongthida P, Diaz RM, Galivo F, et al. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res 2010;70(11):4539-49
5. Le Boeuf F, Diallo JS, McCart JA, et al. Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 2010;18(5):888-95
6. Kaliberova LN, Krendelchtchikova V, Harmon DK, et al. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma. Cancer Gene Ther 2009;16(10):794-805
7. Ottolino-Perry K, Diallo JS, Lichty BD, et al. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010;18(2):251-63
8. Kaufman HL, Bines SD. OPTIM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010;6(6):941-9
9. Alain T, Lun X, Martineau Y, et al. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci USA 2010;107(4):1576-81
10. Wong HH, Lemoine NR, Wang Y. Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses 2010;2(1):78-106
11. Cerullo V, Pesonen S, Diaconu I, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010;70(11):4297-309
12. Diallo JS, Le Boeuf F, Lai F, et al. A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther 2010;18(6):1123-9
13. Watanabe Y, Kojima T, Kagawa S, et al. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy. Oncogene 2010;29(8):1145-54
14. Ziauddin MF, Guo ZS, O'Malley ME, et al. TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. Gene Ther 2010;17(4):550-9
15. Biesecker M, Kimn JH, Lu H, et al. Optimization of virotherapy for cancer. Bull Math Biol 2010;72(2):469-89
16. Paiva LR, Binny C, Ferreira SC Jr, Martins ML. A multiscale mathematical model for oncolytic virotherapy. Cancer Res 2009;69(3):1205-11
17. Wodarz D, Komarova N. Towards predictive computational models of oncolytic virus therapy: basis for experimental validation and model selection. PLoS ONE 2009; 4(1):e4271
18. Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010;17(3):718-30
19. Sivendran S, Pan M, Kaufman HL, Saenger Y. Herpes simplex virus oncolytic vaccine therapy in melanoma. Expert Opin Biol Ther 2010;10(7):1145-53
20. Dias JD, Liikanen I, Guse K, et al. Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1. Clin Cancer Res 2010;16(9):2540-9
21. Onimaru M, Ohuchida K, Mizumoto K, et al. hTERT-promoter-dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication-defective adenovirus vectors in pancreatic cancer cells. Cancer Sci 2010;101(3):735-42
22. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74
23. Wojton J, Kaur B. Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev 2010;21(2-3):127-34
24. Kaur B, Cripe TP, Chiocca EA. "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther 2009;9(5):341-55
25. Butler JM, Kobayashi H, Rafii S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 2010;10(2):138-46
26. Dey M, Ulasov IV, Tyler MA, et al. Cancer stem cells: the final frontier for glioma virotherapy. Stem Cell Rev 2011;7(1):119-29
27. Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010;468(7325):824-8
28. Rahadiani N, Ikeda J-I, Mamat S, et al. Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications. Cancer Sci 2011;102(4):903-8
29. Ishida D, Nawa A, Tanino T, et al. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus. Cancer Lett 2010;288(1):17-27
30. Zhang JF, Wei F, Wang HP, et al. Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo. J Exp Clin Cancer Res 2010;29:52
31. Guedan S, Rojas JJ, Gros A, et al. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 2010;18(7):1275-83
32. Alonso MM, Gomez-Manzano C, Bekele BN, et al. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res 2007;67(24):11499-504
33. Zheng JN, Pei DS, Mao LJ, et al. Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis. Cancer Gene Ther 2010;17(1):28-36
34. Yang SW, Cody JJ, Rivera AA, et al. Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy. Clin Cancer Res 2011;17(3):538-49
35. Breitbach CJ, Paterson JM, Lemay CG, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007;15(9):1686-93
36. Aghi MK, Liu TC, Rabkin S, Martuza RL. Hypoxia enhances the replication of oncolytic herpes simplex virus. Mol Ther 2009;17(1):51-6
37. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012;12(1):9-22
38. Hay JG. The potential impact of hypoxia on the success of oncolytic virotherapy. Curr Opin Mol Ther 2005;7(4):353-8
39. Yasui T, Ohuchida K, Zhao M, et al. Tumor-stroma interactions reduce the efficacy of adenoviral therapy through the HGF-MET pathway. Cancer Sci 2011;102(2):484-91
40. Doloff JC, Waxman DJ. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT. Cancer Gene Ther 2011;18(3):153-66
41. Rojas JJ, Guedan S, Searle PF, et al. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses. Mol Ther 2010;18(11):1960-71
42. Cascallo M, Alonso MM, Rojas JJ, et al. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol Ther 2007;15(9):1607-15
43. Leja J, Nilsson B, Yu D, et al. Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability. PLoS ONE 2010;5(1):e8916
44. Budde A, Schneiderhan-Marra N, Petersen G, Brune B. Retinoblastoma susceptibility gene product pRB activates hypoxia-inducible factor-1 (HIF-1). Oncogene 2005;24(10):1802-8
45. Gabellini C, Del Bufalo D, Zupi G. Involvement of RB gene family in tumor angiogenesis. Oncogene 2006;25(38):5326-32
46. Iaquinta PJ, Lees JA. Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 2007;19(6):649-57
47. Koong AC, Mehta VK, Le QT, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000;48(4):919-22
48. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut 2007;56(8):1134-52
49. du Rieu MC, Torrisani J, Selves J, et al. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 2010;56(4):603-12
50. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Postgrad Med J 2008;84(995):478-97
51. Ho AS, Huang X, Cao H, et al. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol 2010;3(2):109
52. Wennier S, Li S, McFadden G. Oncolytic virotherapy for pancreatic cancer. Expert Rev Mol Med 2011;13(1):e18
53. Bortolanza S, Bunuales M, Otano I, et al. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther 2009;17(4):614-22
54. Monsurro V, Beghelli S, Wang R, et al. Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy. J Transl Med 2010;8(10):10
55. Murphy AM, Besmer DM, Moerdyk-Schauwecker M, et al. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol 2012;86(6):3073-87
56. Huang X, Ding L, Bennewith KL, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009;35(6):856-67
57. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 2009;69(3):1221-9
58. Hiley CT, Yuan M, Lemoine NR, Wang Y. Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours. Gene Ther 2010;17(2):281-7
59. Chun YS, Adusumilli PS, Fong Y. Employing tumor hypoxia for oncolytic therapy in breast cancer. J Mammary Gland Biol Neoplasia 2005;10(4):311-18
60. Longo SL, Griffith C, Glass A, et al. Development of an oncolytic herpes simplex virus using a tumor-specific HIFresponsive promoter. Cancer Gene Ther 2011;18(2):123-34
61. Carson J, Haddad D, Bressman M, Fong Y. Oncolytic herpes simplex virus 1 (HSV-1) vectors: increasing treatment efficacy and range through strategic virus design. Drugs Future 2010;35(3):183-95
62. Willmon C, Harrington K, Kottke T, et al. Cell carriers for oncolytic viruses: fed ex for cancer therapy. Mol Ther 2009;17(10):1667-76
63. Riolobos L, Valle N, Hernando E, et al. Viral oncolysis that targets Raf-1 signaling control of nuclear transport. J Virol 2010;84(4):2090-9
64. Lacroix J, Leuchs B, Li J, et al. Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells. Int J Cancer 2010;127(5):1230-9
65. Hogg RT, Thorpe P, Gerard RD. Retargeting adenoviral vectors to improve gene transfer into tumors. Cancer Gene Ther 2011;18(4):275-87
66. Yoo JY, Ryu J, Gao R, et al. Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-oncolytic virus. J Gene Med 2010;12(7):586-95
67. Germano IM, Emdad L, Qadeer ZA, et al. Embryonic stem cell (ESC)- mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas. Cancer Gene Ther 2010;17(9):664-74
68. Hamed HA, Yacoub A, Park MA, et al. Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances MDA-7/IL-24 therapy of malignant glioma. Mol Ther 2010;18(6):1130-42
69. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007;8(8):573-87
70. Coughlan L, Alba R, Parker AL, et al. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2010;2(10):2290-355
71. Nakashima H, Kaur B, Chiocca EA. Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev 2010;21(2-3):119-26
72. Hochberg M, Kunicher N, Gilead L, et al. Tropism of herpes simplex virus type 1 to nonmelanoma skin cancers. Br J Dermatol 2011;164(2):273-81
73. Power AT, Bell JC. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther 2007;15(4):660-5
74. Power AT, Bell JC. Taming the Trojan horse: optimizing dynamic carrier cell/ oncolytic virus systems for cancer biotherapy. Gene Ther 2008;15(10):772-9
75. Raykov Z, Rommelaere J. Potential of tumour cells for delivering oncolytic viruses. Gene Ther 2008;15(10):704-10
76. Stanford MM, Barrett JW, Nazarian SH, et al. Oncolytic virotherapy synergism with signaling inhibitors: rapamycin increases myxoma virus tropism for human tumor cells. J Virol 2007;81(3):1251-60
77. Kim M, Williamson C, Prudhomme J, et al. The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. Oncogene 2010;29(27):3990-6
78. Castro MG, Candolfi M, Kroeger K, et al. Gene therapy and targeted toxins for glioma. Curr Gene Ther 2011;11(3):155-80
79. Carlisle RC, Benjamin R, Briggs SS, et al. Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera. J Gene Med 2008;10(4):400-11
80. Kelly EJ, Russell SJ. MicroRNAs and the regulation of vector tropism. Mol Ther 2009;17(3):409-16
81. Leber MF, Bossow S, Leonard VH, et al. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. Mol Ther 2011;19(6):1097-106
82. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480(7378):480-9
83. Disis ML. Immune regulation of cancer. J Clin Oncol 2010;28(29):4531-8
84. Mlecnik B, Bindea G, Pages F, Galon J. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev 2011;30(1):5-12
85. Bindea G, Mlecnik B, Fridman WH, et al. Natural immunity to cancer in humans. Curr Opin Immunol 2010;22(2):215-22
86. Tosolini M, Kirilovsky A, Mlecnik B, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res 2011;71(4):1263-71
87. Hu Z, Robbins JS, Pister A, et al. A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy. Cancer Gene Ther 2010;17(4):235-43
88. Kitamura A, Matsushita K, Takiguchi Y, et al. Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma. Cancer Sci 2011;102(7):1366-73
89. Altomonte J, Ebert O. Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses. Microb Biotechnol 2012;5(2):251-9
90. Markert JM, Liechty PG, Wang W, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2008;17(1):199-207
91. Echchgadda I, Chang TH, Sabbah A, et al. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense. BMC Cancer 2011;11:43
92. Akinlolu O, Ottolino-Perry K, McCart JA, Reilly RM. Antiproliferative effects of 111In- or 177Lu-DOTATOC on cells exposed to low multiplicity-of- infection double-deleted vaccinia virus encoding somatostatin subtype-2 receptor. Cancer Biother Radiopharm 2010;25(3):325-33
93. Chen HH, Cawood R, El-Sherbini Y, et al. Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia. Mol Ther 2011;19(1):67-75
94. Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 2011;19(6):1008-16
95. Sobol PT, Boudreau JE, Stephenson K, et al. Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther 2011;19(2):335-44
96. Li J, O'Malley M, Urban J, et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther 2011;19(4):650-7
97. Alemany R, Cascallo M. Oncolyticviruses from the perspective of the immune system. Future Microbiol 2009;4:527-36
98. Fujiwara S, Nawa A, Luo C, et al. Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer. Cancer Gene Ther 2011;18(2):77-86
99. Liu X, Cao X, Wei R, et al. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL. Cancer Gene Ther 2012;19(1):49-57
100. Breitbach CJ, Reid T, Burke J, et al. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev 2010;21(2-3):85-9
101. Eager RM, Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther 2011;18(5):305-17
102. Sasaki T, Tazawa H, Hasei J, et al. Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas. Clin Cancer Res 2011;17(7):1828-38
103. Parato KA, Breitbach CJ, Le Boeuf F, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 2012;20(4):749-58
104. Steele L, Errington F, Prestwich R, et al. Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-kappaB mediated and supports innate and adaptive anti-tumour immune priming. Mol Cancer 2011;10:20
105. Thorne SH, Liang W, Sampath P, et al. Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy. Mol Ther 2010;18(9):1698-705
106. Meng X, Nakamura T, Okazaki T, et al. Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma. Mol Ther 2010;18(3):544-51
107. Hogg RT, Garcia JA, Gerard RD. Adenoviral targeting of gene expression to tumors. Cancer Gene Ther 2010;17(6):375-86
108. Borovjagin AV, McNally LR, Wang M, et al. Noninvasive monitoring of mRFP1- and mCherry-labeled oncolytic adenoviruses in an orthotopic breast cancer model by spectral imaging. Mol Imaging 2010;9(2):59-75
109. Wennier ST, Liu J, Li S, et al. Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer. Mol Ther 2012;20(4):759-68
110. Redaelli M, Franceschi V, Capocefalo A, et al. Herpes simplex virus type 1 thymidine kinase-armed bovine herpesvirus type 4-based vector displays enhanced oncolytic properties in immunocompetent orthotopic syngenic mouse and rat glioma models. Neuro Oncol 2012;14(3):288-301
111. Paglino JC, van den Pol AN. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J Virol 2011;85(18):9346-58
112. Song TJ, Haddad D, Adusumilli P, et al. Molecular network pathways and functional analysis of tumor signatures associated with development of resistance to viral gene therapy. Cancer Gene Ther 2012;19(1):38-48
113. Vile R, Melcher A. An intravenous stimulus package for oncolytic virotherapy. Mol Ther 2011;19(11):1930-2
114. Lavilla-Alonso S, Abo-Ramadan U, Halavaara J, et al. Optimized mouse model for the imaging of tumor metastasis upon experimental therapy. PLoS One 2011;6(11):e26810
115. Heikkila JE, Vaha-Koskela MJ, Ruotsalainen JJ, et al. Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PLoS One 2010;5(1):e8603
116. Borrell B. How accurate are cancer cell lines? Nature 2010;463(7283):858
117. Pencavel T, Seth R, Hayes A, et al. Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow? Gene Ther 2010;17(8):949-60
118. Huszthy PC, Immervoll H, Wang J, et al. Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment. Gene Ther 2010;17(2):202-16
119. Dhar D, Spencer JF, Toth K, Wold WSM. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Mol Ther 2009;17(10):1724-32
120. Dias JD, Guse K, Nokisalmi P, et al. Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures. Eur J Cancer 2010;46(3):625-35
121. Sher Y-P, Liu S-J, Chang C-M, et al. Cancer-targeted BikDD gene therapy elicits protective antitumor immunity against lung cancer. Mol Cancer Ther 2011;10(4):637-47
122. Basse B, Joseph WR, Marshall ES, Baguley BC. Analysis of radiation-induced changes to human melanoma cultures using a mathematical model. Cell Prolif 2010;43(2):139-46
123. Turner C, Kohandel M. Investigating the link between epithelial- mesenchymal transition and the cancer stem cell phenotype: a mathematical approach. J Theor Biol 2010;265(3):329-35
124. Davydova J, Gavrikova T, Brown EJ, et al. In vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy. Cancer Sci 2010;101(2):474-81
125. Sen Sharma K, Moorkanat G, Qiao D, et al. Efficient fluorescence-based imaging methods for quantitating infectivity and oncolytic efficacy of Newcastle disease virus. J Virol Methods 2010;163(2):390-7
126. Alderton GK. Microenvironment: protective surroundings. Nat Rev Cancer 2012;12(1):2-3
127. Lane DP, Cheok CF, Lain S. P53-based cancer therapy. Cold Spring Harb Perspect Biol 2010;2(9):a001222
128. Kuhnel F, Gurlevik E, Wirth TC, et al. Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues. Mol Ther 2010;18(5):936-46
129. Ouellette MM, Wright WE, Shay JW. Targeting telomerase-expressing cancer cells. J Cell Mol Med 2011;15(7):1433-42
130. Wang X, Su C, Cao H, et al. A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers. Mol Cancer Ther 2008;7(6):1598-603
131. Shen CX, Wen Z, Qian YH, et al. Targeted gene therapy of nasopharyngeal cancer in vitro and in vivo by enhanced thymidine kinase expression driven by human TERT promoter and CMV enhancer. J Exp Clin Cancer Res 2010;29:94
132. Kanai R, Wakimoto H, Martuza RL, Rabkin SD. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res 2011;17(11):3686-96
133. Zhang KX, Matsui Y, Hadaschik BA, et al. Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death. Int J Cancer 2010;127(4):830-8
134. Tanaka M, Shimbo T, Kikuchi Y, et al. Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon. Int J Cancer 2010;126(8):1982-91
135. Tiwari R, Bargmann W, Bose HR Jr. Activation of the TGF-beta/Smad signaling pathway in oncogenic transformation by v-Rel. Virology 2011;413(1):60-71
136. Saloura V, Wang LC, Fridlender ZG, et al. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther 2010;21(1):51-64
137. Miller JM, Bidula SM, Jensen TM, Reiss CS. Vesicular stomatitis virus modified with single chain IL-23 exhibits oncolytic activity against tumor cells in vitro and in vivo. Int J Infereron Cytokine Mediator Res 2010;2010(2):63-72
138. Li H, Peng KW, Dingli D, et al. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther 2010;17(8):550-8
139. Tsai YS, Shiau AL, Chen YF, et al. Enhancement of antitumor activity of gammaretrovirus carrying IL-12 gene through genetic modification of envelope targeting HER2 receptor: a promising strategy for bladder cancer therapy. Cancer Gene Ther 2010;17(1):37-48
140. Fan JK, Wei N, Ding M, et al. Targeting gene-virotherapy for prostate cancer by DD3-driven oncolytic virus-harboring interleukin-24 gene. Int J Cancer 2010;127(3):707-17
141. Yang L, Wang L, Su XQ, et al. Suppression of ovarian cancer growth via systemic administration with liposome-encapsulated adenovirusencoding endostatin. Cancer Gene Ther 2010;17(1):49-57
142. Li X, Liu Y, Tang Y, et al. Docetaxel increases antitumor efficacy of oncolytic prostate-restricted replicative adenovirus by enhancing cell killing and virus distribution. J Gene Med 2010;12(6):516-27
143. Shim SH, Lee CT, Hun Hah J, et al. Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma. Cancer Sci 2010;101(2):482-7
144. Alvarez-Breckenridge CA, Yu J, Kaur B, et al. Deciphering the multifaceted relationship between oncolytic viruses and natural killer cells. Adv Virol 2012;2012:702839
145. Liu C, Russell SJ, Peng KW. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther 2010;18(6):1155-64
146. Lee JH, Roh MS, Lee YK, et al. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther 2010;17(2):73-9
147. Heinemann L, Simpson GR, Annels NE, et al. The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis. Mol Ther 2010;18(12):2085-93
148. Hardcastle J, Kurozumi K, Dmitrieva N, et al. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 2010;18(2):285-94
149. Kottke T, Hall G, Pulido J, et al. Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest 2010;120(5):1551-60
150. Breitbach CJ, Thorne SH, Bell JC, Kirn DH. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594. Curr Pharm Biotechnol 2011; Epub ahead of print
151. Heo J, Breitbach CJ, Moon A, et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther 2011;19(6):1170-9
152. Hwang TH, Moon A, Burke J, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther 2011;19(10):1913-22
153. Lun X, Chan J, Zhou H, et al. Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol Ther 2010;18(11):1927-36
154. Ishida D, Nawa A, Tanino T, et al. Enhanced cytotoxicity with a novel system combining the paclitaxel-2¢-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus. Cancer Lett 2010;288(1):17-27
155. Price DL, Lin SF, Han Z, et al. Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2010;136(2):151-8
156. Simpson GR, Horvath A, Annels NE, et al. Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. Br J Cancer 2012;106(3):496-507
157. Zaoui K, Bossow S, Grossardt C, et al. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus. Cancer Gene Ther 2012;19(3):181-91
158. Yamada S, Kuroda T, Fuchs BC, et al. Oncolytic Herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation. Cancer Gene Ther 2012;19(3):160-70
159. Tazawa H, Yano S, Yoshida R, et al. Genetically engineered oncolytic adenovirus induces autophagic cell death through an E2F1-microRNA-7-epidermal growth factor receptor axis. Int J Cancer 2012; doi: 10.1002/ijc.27589 [Epub ahead of print]
160. Sakurai F, Katayama K, Mizuguchi H. MicroRNA-regulated transgene expression systems for gene therapy and virotherapy. Front Biosci 2012;17:2389-401
161. Fu X, Rivera A, Tao L, et al. Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells. Mol Ther 2012;20(2):339-46
162. Sugio K, Sakurai F, Katayama K, et al. Enhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequences. Clin Cancer Res 2011;17(9):2807-18
163. Jin H, Lv S, Yang J, et al. Use of microRNA Let-7 to control the replication specificity of oncolytic adenovirus in hepatocellular carcinoma cells. PLoS ONE 2011;6(7):e21307
164. Hikichi M, Kidokoro M, Haraguchi T, et al. MicroRNA regulation of glycoprotein B5R in oncolytic vaccinia virus reduces viral pathogenicity without impairing its antitumor efficacy. Mol Ther 2011;19(6):1107-15
165. Kelly EJ, Nace R, Barber GN, Russell SJ. Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol 2010;84(3):1550-62
166. Heinemann L, Simpson GR, Boxall A, et al. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer 2011;11:221
167. Le Boeuf F, Bell JC. United virus: the oncolytic tag-team against cancer!. Cytokine Growth Factor Rev 2010;21(2-3):205-11
168. Libertini S, Abagnale A, Passaro C, et al. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. Endocr Relat Cancer 2011;18(1):129-41
169. Skelding KA, Barry RD, Shafren DR. Enhanced oncolysis mediated by coxsackievirus A21 in combination with doxorubicin hydrochloride. Invest New Drugs 2012;30(2):568-81
170. Ganesh S, Gonzalez-Edick M, Gibbons D, et al. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res 2008;14(12):3933-41
171. Nguyen TL, Wilson MG, Hiscott J. Oncolytic viruses and histone deacetylase inhibitors-A multi-pronged strategy to target tumor cells. Cytokine Growth Factor Rev 2010;21(2-3):153-9
172. Ferguson MS, Lemoine NR, Wang Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol 2012;2012:805629